Polymer Drugs in the Clinical Stage

Advantages and Prospects

ISBN: 978-0-306-47471-2 (Print) 978-0-306-47932-8 (Online)

Table of contents (13 chapters)

  1. No Access

    Book Chapter

    Pages 1-27

    Challenges in Polymer Therapeutics

  2. No Access

    Book Chapter

    Pages 29-49

    Factors and Mechanism of “EPR” Effect and the Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS

  3. No Access

    Book Chapter

    Pages 51-58

    PEG-Adenosine Deaminase and PEG-Asparaginase

  4. No Access

    Book Chapter

    Pages 59-67

    Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C

  5. No Access

    Book Chapter

    Pages 69-79

    PEG-Methioninase

  6. No Access

    Book Chapter

    Pages 81-99

    Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103) [XYOTAX™], a Biodegradable Polymeric Drug Conjugate

  7. No Access

    Book Chapter

    Pages 101-123

    HPMA Copolymer Delivery of Chemotherapy and Photodynamic Therapy in Ovarian Cancer

  8. No Access

    Book Chapter

    Pages 125-143

    Drug-HPMA-HuIg Conjugates Effective Against Human Solid Cancer

  9. No Access

    Book Chapter

    Pages 145-153

    CM-Dextran-Polyalcohol-Camptothecin Conjugate

  10. No Access

    Book Chapter

    Pages 155-177

    Polymeric Micelle Drug Carrier Systems: PEG-PAsp(Dox) and Second Generation of Micellar Drugs

  11. No Access

    Book Chapter

    Pages 178-194

    An Interim Analysis of Phase I Clinical Trial of MCC-465, a Doxorubicin (DXR) Encapsulated in PEG-immunoliposome, in Patients with Metastatic Stomach Cancer

  12. No Access

    Book Chapter

    Pages 195-205

    Polymer Conjugates for Imaging

  13. No Access

    Book Chapter

    Pages 207-216

    S-Nitrosylated Polyethylene Glycol-conjugated Hemoglobin Derivative as a Candidate Material for Oxygen Therapeutics